These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1490 related articles for article (PubMed ID: 10235151)

  • 1. Natural history of progression after PSA elevation following radical prostatectomy.
    Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
    JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
    Antonarakis ES; Feng Z; Trock BJ; Humphreys EB; Carducci MA; Partin AW; Walsh PC; Eisenberger MA
    BJU Int; 2012 Jan; 109(1):32-9. PubMed ID: 21777360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    JAMA; 2005 Jul; 294(4):433-9. PubMed ID: 16046649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
    Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
    Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
    Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
    Pound CR; Partin AW; Epstein JI; Walsh PC
    Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The meaning of PSA progression after radical prostatectomy. Preliminary results].
    Luján Galán M; Pascual Mateo C; Rodríguez García N; Chiva Robles V; Escalera Almendros C; Angulo Cuesta J; Berenguer Sánchez A
    Actas Urol Esp; 2006 Apr; 30(4):353-8. PubMed ID: 16838606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.
    Trapasso JG; deKernion JB; Smith RB; Dorey F
    J Urol; 1994 Nov; 152(5 Pt 2):1821-5. PubMed ID: 7523728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
    Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC
    J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.
    Pound CR; Christens-Barry OW; Gurganus RT; Partin AW; Walsh PC
    J Urol; 1999 Oct; 162(4):1337-40. PubMed ID: 10492192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers and meaning of primary treatment failure.
    Swindle PW; Kattan MW; Scardino PT
    Urol Clin North Am; 2003 May; 30(2):377-401. PubMed ID: 12735513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.